Angiotensin-converting enzyme inhibitor therapy for coronary artery disease and diabetes mellitus

American Journal of Managed Care

Volumn 13, Issue 10, 2007, Pages 560-566

  McConnell, Karen J ^a,b,c   Zadvorny, Emily B ^a,b   Denham, Anne M ^a,b   Kasten, Sheila L ^a,b   Hutka, Kara A ^a,b   Koetting, Cedar R ^a,b   Merenich, John A ^a,b  

^a Clinical Pharmacy Cardiac Risk Service   (United States)

^b UNIVERSITY OF COLORADO   (United States)

^c KAISER PERMANENTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; LISINOPRIL; LOSARTAN;

AGED; ARTICLE; COHORT ANALYSIS; CORONARY ARTERY DISEASE; COUGHING; CREATININE BLOOD LEVEL; DIABETES MELLITUS; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG SAFETY; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; HUMAN; HYPOTENSION; MAJOR CLINICAL STUDY; MALE; PHOSPHATE BLOOD LEVEL; PRIORITY JOURNAL; SIDE EFFECT; SYSTOLIC BLOOD PRESSURE;

ADULT; AGED; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTIHYPERTENSIVE AGENTS; CARDIOTONIC AGENTS; COLORADO; COMORBIDITY; CORONARY ARTERIOSCLEROSIS; DIABETES MELLITUS; DRUG EVALUATION; FEMALE; HEALTH MAINTENANCE ORGANIZATIONS; HUMANS; LISINOPRIL; MALE; MIDDLE AGED; PROSPECTIVE STUDIES;

EID: 35348957335     PISSN: 10880224     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Danchin N, Cucherat M, Thuillez C, Durand E, Kadri Z, Steg P. Angiotensin-converting enzyme inhibitors in patients with coronary artery disease and absence of heart failure of left ventricular systolic dysfunction. Arch Intern Med. 2006;166:787-796.
2. Al-Mallah MH, Tleyjeh IM, Abdel-Latif AA, Weaver WD. Angiotensin-converting enzyme inhibitors in coronary artery disease and preserved left ventricular systolic function. A systematic review and meta analysis of randomized controlled trials. J Am Coll Cardiol. 2006;47:1576-1583.
3. Dagenais GR, Pogue J, Fox K, Simoons ML, Yusuf S. Angiotensin-converting-enzyme inhibitors in stable vascular disease without left ventricular systolic dysfunction or heart failure: a combined analysis of 3 trials. Lancet. 2006;368:581-588.
4. Lonn E, Yusuf S, Dzavik V, et al. Effects of ramipril and vitamin E on atherosclerosis: the Study to Evaluate Carotid Ultrasound changes in patients treated with ramipril and vitamin E (SECURE). Circulation. 2001;103:919-925.
5. Heart Outcomes Prevention Evaluation (HOPE) Study Investigators. Effects of an angiotensin-converting enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med. 2000;342:145-153.
6. European Trial on Reduction of Cardiac Events with Perindopril in Stable Coronary Artery Disease Investigators. Efficacy of perindopril on reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled multicentre trial (the EUROPA study). Lancet. 2003;362:782-788.
7. The PEACE Trial Investigators. Angiotensin-converting-enzyme inhibition in stable coronary artery disease. N Engl J Med. 2004;351:2058-2068.
8. Heart Outcomes Prevention Evaluation (HOPE) Study Investigators. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Lancet. 2000;355:253-259.
9. Daly CA, Fox KM, Remme WJ, Bertrand ME, Ferrari R, Simoons ML. The effect of perindopril on cardiovascular morbidity and mortality in patients with diabetes in the EUROPA study: results from the PERSUADE substudy. Eur Heart J. 2005;26:1369-1378.
10. Smith SC, Allen J, Blair SN, et al. AHA/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update. Circulation. 2006;113:2362-2372.
11. Brown LC, Johnson JA, Majumdar SR, Tsuyuki RT, McAlister FA. Evidence of suboptimal management of cardiovascular risk in patients with type 2 diabetes mellitus and symptomatic atherosclerosis. CMAJ. 2004;171:1189-1192.
12. Olson KL, Rasmussen JR, Sandhoff BG, Merenich JA. Lipid management in patients with coronary artery disease by a clinical pharmacy service in a group model health maintenance organization. Arch Intern Med. 2005;165:49-54.
13. Helling DK, Nelson KM, Ramirez JE, Humphries TL. Kaiser Permanente Colorado Region Pharmacy Department: innovative leader in pharmacy practice. J Am Pharm Assoc. 2006;46:67-76.
14. McConnell KJ, Zadvorny EB, Hardy AM, Delate T, Rasmussen JR, Merenich JA. Coronary artery disease and hypertension: outcomes of a pharmacist-managed blood pressure program. Pharmacotherapy. 2006;26:1333-1341.
15. McConnell KJ, Humphries TL, Raebel MA, Merenich JA. Clinical pharmacy specialist implementation of lisinopril therapy in patients with coronary artery disease and diabetes mellitus. Pharmacotherapy. 2003;23:1564-1572.
16. Lindholm LH, Ibsen H, Dahlof B, et al; LIFE Study Group. Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention for Endpoint Reduction in Hypertension Study (LIFE): a randomised trial against atenolol. Lancet. 2002;359:1004-1010.
17. Parving HH, Lehnert H, Brochner-Mortensen J, Gomis R, Andersen S, Arner P; Irbesartan in Patients with Type 2 Diabetes and Microalbuminuria Study Group. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med. 2001;345:870-878.
18. Brenner BM, Cooper ME, de Zeeuw D, et al; RENAAL Study Investigators. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med. 2001;345:861-869.
19. American Diabetes Association. Standards of medical care in diabetes. Diabetes Care. 2004;27:S15-S35.
20. Luque CA, Vazquez Oriz M. Treatment of ACE inhibitor-induced cough. Pharmacotherapy. 1999;19:804-810.